Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.
  • Page:
  • 1

Synairgen (SNG)     

dreamcatcher - 01 Aug 2015 22:27


Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.
The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.

Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Core to Synairgen’s business strategy is the realisation of value via licensing transactions – as demonstrated through the out-licensing of SNG001 to AstraZeneca in 2014 in a deal worth up to $232m plus royalties.

(AIM:SNG).

http://www.synairgen.com/

Chart.aspx?Provider=EODIntra&Code=SNG&SiChart.aspx?Provider=EODIntra&Code=SNG&Si

Bullshare - 08 Apr 2016 15:21 - 8 of 8

Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.

 - Directors present their latest plans regarding development and growth

 - An opportunity to talk directly to the companies and personally put forward your questions

 - The chance to network with other attendees over drinks and canapés - private investors, wealth managers, fund managers and financial institutions

Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Tuesday 12th April 2016

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Christopher P. Bogart, CEO - Burford Capital (BUR)
• Neil Elton, Group FD - Learning Technologies Group (LTG)
• Jonathan Satchell, Chief Executive - Learning Technologies Group (LTG)
• William Cain, Companies Editor - SHARES
• Bruno Jactel, CEO - TyraTech (TYR)
20.30 
Drinks reception and canapés
21.30 
Close
Attendance is free, but spaces are limited. Register now to secure your place!
Burford Capital (BUR)
Burford Capital (BUR) 

Litigation finance treats litigation claims as financeable assets, just like real estate or receivables. Burford’s capital is used by businesses to pay legal expenses, relieve budget and P&L pressure, and monetize legal claims as the valuable assets they are. Litigation finance can also serve as an accounting tool, allowing businesses to litigate claims without impacting corporate balance sheets.

Learning Technologies Group (LTG)
Learning Technologies Group (LTG) 

Learning Technologies Group plc was created in 2013 by a highly experienced team of successful corporate leaders and learning technologies professionals to provide a comprehensive and integrated range of e-learning services and technologies to corporate and government clients. LTG is making good progress towards its goal of establishing a substantial global organisation of specialist digital learning businesses from Europe, US, Latin America and Asia to form a market-leading learning technologies agency.

SHARES
SHARES 

SHARES is the UK's leading investment magazine. Published weekly, SHARES provides its readers with a wealth of investment information covering areas such as large, mid and small cap stocks, commodities, bonds, funds, forex, ETFs, ISAs and much more and enjoyed by 15,000 readers across print, web and mobile.

TyraTech (TYR)
TyraTech (TYR) 

TyraTech, Inc. was established in 2004 and has developed a unique patented technology to enhance the activity of plant-based ingredients against insects and parasites.

In 2014, TyraTech launched Vamousse® head lice treatment and shampoo, now stocked in 20,000 stores in the USA & 7,000 stores in the UK. With Vamousse, TyraTech has unlocked the value of its technology platform and shown that its products can be a commercial success.

The commercial success of the Vamousse head lice range can be reproduced in significantly larger markets eg insect control in livestock premises.

TyraTech, Inc. made its Initial Public Offering in June 2007 on AIM, where it trades under two separate common stock share listings (TYR and TYRU). 

Sponsored by:
AJ Bell Youinvest
  • Page:
  • 1
Register now or login to post to this thread.